Merck and Moderna Report Positive Phase 3 INTerpath-001 Trial Results
Merck and Moderna announced positive recurrence-free and distant metastasis-free survival results for intismeran autogene plus Keytruda in the Phase 3 INTerpath-001 trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck Showcases First — Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
For best results when printing this announcement, please click on link below: Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026 INTerpath-001 data to be presented in Presidential Symposium, featuring the first Phase 3 results
NeOnc included in cancer breakthrough roundup
A GlobeNewswire press release highlights NeOnc Technologies among several 2026 cancer-development updates, including its Phase 2a NEO100 survival findings in recurrent high-grade brain cancer. The piece is a promotional roundup rather than a new market-moving company event.
Target tops Street in Q2; Lowe’s delivers mixed 2026 view
Target reports better-than-expected second-quarter earnings while Lowe’s posts mixed second-quarter 2026 results and narrows its full-year outlook below Wall Street estimates.
Merck, Moderna report positive phase 3 melanoma results
Merck and Moderna say the phase 3 INTERPATH-001 trial of intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in completely resected Stage IIb-IV melanoma.